Adjustable Artificial Sphincter Victo in the Treatment of Male Incontinence Due to Prostate Surgery
Launched by UNIVERSITY HOSPITAL OSTRAVA · Jan 25, 2024
Trial Information
Current as of November 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of a device called the Victo adjustable artificial sphincter, which is designed to help men who experience urinary incontinence after prostate surgery. Urinary incontinence means having trouble controlling when you urinate, which can be a common issue following prostate procedures. The goal of the study is to see if this device can improve the quality of life for men dealing with this problem.
To participate in the trial, men aged 65 to 74 who have urinary incontinence due to previous prostate surgery can apply. Participants will be the first to receive this device, and they will need to agree to give informed consent, meaning they understand what the study involves and agree to take part. This study is currently recruiting participants, and there are no major exclusion criteria, so if you meet the age and condition requirements, you might be eligible to join. Throughout the trial, participants will be closely monitored to assess how well the device works and ensure their safety.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • urinary incontinence due to previous prostate surgery
- • primo-implantation of the artificial urinary sphincter
- • subject willing and able to give informed consent
- Exclusion Criteria:
- • - none
About University Hospital Ostrava
University Hospital Ostrava is a leading medical research institution located in Ostrava, Czech Republic, dedicated to advancing healthcare through innovative clinical trials and research initiatives. As a prominent sponsor of clinical studies, the hospital combines cutting-edge medical technology with a commitment to patient-centered care, fostering collaborations among multidisciplinary teams of healthcare professionals and researchers. With a focus on ethical standards and regulatory compliance, University Hospital Ostrava aims to contribute to the development of new therapies and improve treatment outcomes across various medical fields. Its robust research infrastructure and dedication to scientific excellence position it as a key player in the advancement of medical knowledge and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ostrava, Moravian Silesian Region, Czechia
Patients applied
Trial Officials
Jan Krhut, prof.,MD, PhD
Principal Investigator
University Hospital Ostrava
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported